FIELD: biotechnology.
SUBSTANCE: double-stranded oligoribonucleotide comprises the sequence of the antisense chain SEQ ID NO: 28: 5' AGUAGUUUCCAUAGGUCUG 3' and the sequence of the sense chain SEQ ID NO: 5: 5' CAGACCUAUGGAAACUACU 3'. And it is able to cause down regulation of expression of the human gene p53, for example, when used in a pharmaceutical formulation comprising this compound and a pharmaceutically acceptable carrier. This oligoribonucleotide can also be used for treatment of acute renal failure.
EFFECT: expansion of the scope of application of the compound.
12 cl, 7 dwg, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OLIGIRIBONUCLEOTIDES AND METHODS OF THEIR APPLICATION FOR TREATMENT OF ACUTE RENAL FAILURE AND OTHER DISEASES | 2005 |
|
RU2434942C2 |
| TREATMENT OF CNS DISORDERS | 2007 |
|
RU2426544C2 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2618688C2 |
| TREATMENT OF TUMORS OF DISEASES RELATED TO THE GENOM-SUPPRESSOR BY THERAPY OF NATURAL TRANSCRIPT INHIBITION IN ANTI-SIGNIFICANT ORIENTATION REGARDING THIS GENE | 2009 |
|
RU2746478C2 |
| TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION | 2009 |
|
RU2620970C2 |
| TREATMENT OF INTESTINAL DISEASES | 2006 |
|
RU2418594C2 |
| HSP47 EXPRESSION MODULATION | 2010 |
|
RU2575056C2 |
| TREATING SIRTIUN 1 (SIRT1)-RELATED DISEASES BY INHIBITON OF NATURAL ANTISENSE TRANSCRIPT | 2009 |
|
RU2551234C2 |
| MEDIATED PHKi INHIBITION OF Rho-KINASE FOR TREATING OPHTHALMIC DISORDERS | 2006 |
|
RU2432165C2 |
| iRNA-MEDIATED INHIBITION OF TUMOUR NECROSIS FACTOR-( RELATED CONDITIONS | 2007 |
|
RU2469090C2 |
